BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34839996)

  • 1. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
    Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H; Kryštof V
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
    Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 10. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D; Wang J; Hong J
    Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of BTK inhibitors for the treatment of B-cell malignancies.
    Kim HO
    Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Means and Challenges in the Targeting of BTK.
    Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
    Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.